Quick answer: latest quarter results, by ticker or company name

Reported Q: Q1 2024 Rev YoY: +10.0% EPS YoY: -98.2% Move: +0.50%

Walgreens Boots Alliance

WBA

$11.98 0.50%

Exchange NASDAQ Sector Healthcare Industry Medical Pharmaceuticals

Q1 2024

Published: Jan 4, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for WBA

Reported

Report Date

Jan 4, 2024

Quarter Q1 2024

Revenue

36.71B

YoY: +10.0%

EPS

-0.08

YoY: -98.2%

Market Move

+0.50%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $36.71B up 10% year-over-year
EPS of $-0.08 decreased by 98.2% from previous year
Gross margin of 18.4%
Net income of -67.00M
"Tim Wentworth: 'Managing through the accumulating consumer pressures from inflation and depleted savings... We are navigating the accumulated consumer pressures.'" - Tim Wentworth, CEO

WBA

Walgreens Boots Alliance Inc

Period Q1 2024

Currency USD

Report Type Quarterly Earnings

Generated Feb 10, 2026

Executive Summary

Walgreens Boots Alliance (WBA) reported unplanned results for Q1 2024, demonstrating resilience amid a challenging retail environment. The company generated revenue of $36.71 billion, up 8.7% on a constant currency basis. However, the net loss attributable to shareholders was $67 million, corresponding to an adjusted EPS of $0.66, representing a 44% decline year-over-year. Management emphasized ongoing cost discipline and strategic initiatives in U.S. Healthcare, particularly through VillageMD, which is evolving as a pivotal segment for future growth. Despite adverse market conditions, including inflationary pressures and a weaker respiratory season, WBA affirmed its full-year adjusted EPS guidance, reflecting confidence in its operational adaptability and market position.

Key Performance Indicators

Revenue

Increasing

36.71B

QoQ: 3.63% | YoY: 9.96%

Gross Profit

Decreasing

6.77B

18.44% margin

QoQ: 4.56% | YoY: -2.63%

Operating Income

Decreasing

-39.00M

QoQ: -91.35% | YoY: -99.37%

Net Income

Decreasing

-67.00M

QoQ: -62.78% | YoY: -98.20%

EPS

Decreasing

-0.08

QoQ: -63.05% | YoY: -98.20%

Revenue Trend

Margin Analysis

Financial Highlights

Financial Performance:
- Revenue: $36.71 billion (up 8.7% YoY constant currency basis)
- Net Income: -$67 million
- Adjusted EPS: $0.66 (down 44% YoY)
- Gross Profit Margin: 18.43%

Trends:
- U.S. Retail Pharmacy Sales Growth: 6.4%, driven by pharmacy services despite a 6.1% decline in retail.
- International Segment Growth: 4.4%, with Boots UK showing resilience and share gains.
- Within U.S. Healthcare: Revenue soared 95% YoY, largely attributed to the Summit Health acquisition.

Management indicated that operating cash flow was negatively impacted by seasonal inventory builds and reimbursement timing, but expects to achieve about $1 billion in cost savings in the current year, a move complemented by a significant 48% cut to quarterly dividends to support capital investments.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	36.71B	9.96%	3.63%
Gross Profit	6.77B	-2.63%	4.56%
Operating Income	-39.00M	-99.37%	-91.35%
Net Income	-67.00M	-98.20%	-62.78%
EPS	-0.08	-98.20%	-63.05%

Key Financial Ratios

Gross Profit Margin

Weak

18.40%

Gross profit margin is below industry norms, profitability concerns

Operating Profit Margin

Weak

0.00%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

0.00%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

0.00%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

0.00%

Return on equity suggests inefficient capital allocation

Current Ratio

Concern

0.66

Current ratio below safe levels, potential liquidity risk

Debt to Equity

High Risk

1.22

Debt-to-equity indicates high leverage and elevated financial risk

P/E Ratio

Negative

-64.21x

Negative earnings make P/E ratio not meaningful

Price to Book

Undervalued

0.62x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q1 2025	39,459.00	-0.31	+7.5%	View
Q4 2024	37,547.00	-3.48	+6.0%	View
Q3 2024	36,351.00	0.40	+2.6%	View
Q2 2024	37,052.00	-6.85	+6.3%	View
Q1 2024	36,707.00	-0.08	+10.0%	View

WBA

Walgreens Boots Alliance

Q1 2025 Report

Walgreens Boots Alliance Inc (WBA) Q1 2025 Financial Results Report: Navigating Challenges Amid Strategic Optimizations...

Read full report

WBA

Walgreens Boots Alliance

Q4 2024 Report

Walgreens Boots Alliance Inc (WBA) Q4 2024 Financial Results: Navigating Challenges Amid Transformation...

Read full report

WBA

Walgreens Boots Alliance

Q3 2024 Report

Walgreens Boots Alliance Inc (WBA) Q3 2024 Financial Results Report: A Navigational Update in a Challenging Environment...

Read full report

WBA

Walgreens Boots Alliance

Q2 2024 Report

Walgreens Boots Alliance Inc (WBA) Q2 2024 Financial Results: Navigating Challenges with Strategic Depth...

Read full report

Walgreens Boots Alliance (WBA) Q1 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More WBA Quarterly Reports

WBA

WBA

WBA

WBA

Q1 2024 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

WBA Full Profile

WBA Financial Statements

Earnings Calendar